HoldsUp

Huberman Lab · 2026-01-12 · Andrew Huberman (host), Keith Humphreys

How to Overcome Addiction to Substances or Behaviors | Dr. Keith Humphreys

88 research-tied claims examined: 2 contradicted 6 overstated 8 context 65 supported 7 unverified

2 Contradicted by research
1:40:18Keith Humphreyscontradictedmoderate

Contingency management for addiction treatment is covered by insurance in most places.

"it's covered by insurance now in most places" (said at 1:40:18)

Contingency management (CM) is not covered by health insurance in most places. Despite strong evidence for its efficacy in treating substance use disorders (especially stimulant use disorder), a lack of insurance reimbursement, billing mechanisms, and federal anti-kickback regulatory barriers have historically prevented standard commercial and public insurance coverage. While select states (such as California through Section 1115 Medicaid demonstration waivers) and the Veterans Health Administration have piloted or implemented funded programs, CM remains largely uncovered by standard insurance across most jurisdictions in the United States.

1:44:33Andrew Huberman (host)contradictedhigh

Throat spasms associated with nicotine use are caused by muscarinic acetylcholine stimulation.

"I can do like 2 milligrams of nicotine gum and I notice it gave me spasms in my throat when I wasn't taking it. Um, and I was told that's because of the muscarinic acetylcholine stimulation." (said at 1:44:33)

The claim misidentifies the pharmacological mechanism. Nicotine is a selective agonist for nicotinic acetylcholine receptors (nAChRs), not muscarinic acetylcholine receptors (mAChRs). Nicotine-induced sensory irritation, motor effects, and throat sensations from oral products (such as nicotine gum) are mediated by activation of neuronal nicotinic acetylcholine receptors (nAChRs) on sensory nociceptors (often involving downstream transient receptor potential [TRP] channels) and neuromuscular/autonomic nicotinic pathways, rather than muscarinic receptor stimulation.

6 Overstated
0:12:46Keith Humphreysoverstatedmoderate

Marc Schuckit's studies showed that young male children of alcoholic fathers exhibit less measurable body sway after consuming alcohol and experience fewer hangovers the next day compared to control subjects.

"So Marc Schuckit, who's a superb psychiatrist based in Southern California for most of his career, did some wonderful studies of male children of alcoholic fathers. And one of the things he showed is that when given alcohol, their body sway is less at a level you can't even perceive, but he could measure that. And they had fewer hangovers the next day." (said at 0:12:46)

Marc Schuckit's seminal longitudinal research at UCSD demonstrated that young adult sons of alcoholic fathers exhibit a lower level of response (reduced sensitivity) to alcohol challenges compared to control subjects, which includes significantly less increase in measurable body sway (static ataxia), fewer subjective feelings of intoxication, and attenuated hormonal responses (PMID: 3056066, PMID: 1758993, PMID: 1845531). However, the claim that they experience 'fewer hangovers the next day' is inaccurate; Schuckit's research focused on the acute low level of response (LR) rather than fewer hangovers, and external literature on familial risk of alcoholism actually demonstrates either comparable or greater severity of hangover symptoms among sons of alcoholics (PMID: 2264599). Because the claim bundles the well-documented body sway finding with an inaccurate assertion regarding hangovers, it is graded overstated.

1:12:18Andrew Huberman (host)overstatedmoderate

There is zero scientific evidence that microdosing psilocybin provides any clinical or cognitive benefit.

"My read of the literature—and this might have been updated since—uh is that there is zero evidence that microdosing psilocybin has any benefit." (said at 1:12:18)

The host's assertion that there is 'zero evidence' is overstated. While observational studies, naturalistic surveys, and open-label reports frequently document perceived improvements in mood, focus, and well-being, rigorous double-blind, placebo-controlled randomized trials have largely failed to find significant cognitive, emotional, or clinical benefits of psilocybin microdosing beyond the placebo effect.

1:22:02Keith Humphreysoverstatedmoderate

Starting cigarette smoking at age 13 almost certainly results in addiction, whereas starting at an older age rarely leads to addiction.

"It's also true that if you start smoking cigarettes at my age, you probably will not get addicted, and if you start smoking cigarettes when you're 13, you almost certainly will." (said at 1:22:02)

Extensive epidemiological research demonstrates that early tobacco initiation (at or before age 13) is significantly associated with higher rates and severity of nicotine dependence, heavier smoking, and lower cessation rates compared to later initiation. However, the speaker grossly exaggerates this relative risk gradient into absolute certainties: starting at age 13 does not 'almost certainly' cause addiction (absolute rates of transition to dependence among early experimenters are elevated but well below certainty), and adults initiating regular cigarette smoking remain highly susceptible to nicotine addiction rather than being largely protected.

1:45:18Andrew Huberman (host)overstatedmoderate

Nicotine exerts protective effects against Parkinson's disease and Alzheimer's disease.

"Richard Axel at Columbia, who told me long ago and many times nicotine is protective against Parkinson's and Alzheimer's" (said at 1:45:18)

The claim is overstated. Decades of epidemiological data show an inverse association between tobacco use and the risk of developing Parkinson's disease, and preclinical laboratory studies demonstrate neuroprotective effects of nicotine via nicotinic acetylcholine receptors. However, translation to humans has not demonstrated disease-modifying or neuroprotective efficacy. A major Phase 2 randomized, double-blind, placebo-controlled trial (the NIC-PD study, PMID 38320207) found that 52 weeks of transdermal nicotine did not slow disease progression in early Parkinson's disease. For Alzheimer's disease, smoking is generally associated with increased risk, though pure nicotinic agonists have shown modest, transient symptomatic effects on attention rather than proven neuroprotection.

2:33:11Keith Humphreysoverstatedhigh

A Cochrane Collaboration review found that Alcoholics Anonymous and 12-step facilitation counseling produced roughly 50% higher rates of continuous abstinence from alcohol compared to therapies like cognitive behavioral therapy and motivational enhancement therapy.

"And so finally a few years ago, me, John Kelly, and Marica Ferri did what's called a Cochrane Collaboration uh review... On abstinence outcomes, if you ask like, do people stop entirely? AA and also 12-step facilitation kinds of counseling to help people get into AA was winning, you know, by 50% higher rates routinely of that." (said at 2:33:11)

The 2020 Cochrane systematic review co-authored by Kelly, Humphreys, and Ferri found high-certainty evidence that manualized Alcoholics Anonymous and Twelve-Step Facilitation (AA/TSF) interventions were superior to other active psychological treatments (such as CBT and MET) for continuous alcohol abstinence. However, the pooled effect size at 12 months was a 21% increase in continuous abstinence rates (RR 1.21, 95% CI 1.03 to 1.42), making the claim of '50% higher rates routinely' an overstatement of the meta-analytic findings.

3:18:55Keith Humphreysoverstatedmoderate

The male-to-female ratio for opioid addiction is approximately four men to every one woman.

"You know, opioids probably four men to every one woman" (said at 3:18:55)

While men consistently have higher rates of opioid use disorder and opioid overdose deaths than women, national epidemiologic data show a male-to-female ratio closer to 1.5:1 to 2:1, not 4:1. For example, large-scale analyses of US national mortality data indicate a male-to-female opioid mortality rate ratio of approximately 2.11, and national survey data on substance use disorders find that roughly 63% of individuals with substance use disorders are male (~1.7:1). Stating that the ratio is 'probably four men to every one woman' substantially overstates the gender gap.

8 Needs context
0:04:36Keith Humphreysneeds contextvery low

A 1950s animal study by James Olds demonstrated that rats given the opportunity to self-administer intracranial brain stimulation would continue doing so to the point of starving to death or dehydrating while food pellets and water were readily available.

"So like the classic animal study, you know, is James Olds' study with rats done in the '50s, showing that you could give a a rat the opportunity to give itself brain stimulation, which they enjoy, and that they would continue to do that even as they were starving to death next to a pile of food pellets, or or ran out of water while they were next to water." (said at 0:04:36)

The speaker conflates two classic neurobiology findings. In 1954, James Olds and Peter Milner discovered intracranial self-stimulation (ICSS), demonstrating that rats would repeatedly press levers to receive electrical stimulation in septal and hypothalamic regions (often choosing it over natural rewards or enduring painful footshocks). However, the specific experiment demonstrating that rats would choose intracranial brain stimulation over eating to the point of severe starvation and death was conducted by Aryeh Routtenberg and Joanne Lindy in 1965 (PMID: 5832339). While electrical self-stimulation can indeed outcompete primary biological drives like feeding in animal models, the specific 'starving to death next to food' paradigm belongs to Routtenberg and Lindy's 1965 work rather than Olds' original 1950s study.

0:17:17Keith Humphreysneeds contextmoderate

In genetic studies of alcohol use disorder, the father-to-son transmission link is the strongest observed across sexes.

"No. I mean, there is there is still risk there, for sure, but the father-to-son link is the is the strongest one you see in in genetic studies." (said at 0:17:17)

Early adoption and family studies (such as Cloninger's classification of Type II alcoholism) emphasized prominent father-to-son transmission. While genetic epidemiological literature confirms strong genetic liability in males, broader twin and family studies demonstrate that alcohol use disorder is moderately to highly heritable across both sexes (~50% heritability), and transmission occurs across all parent-offspring dyads rather than being exclusively or definitively strongest from father to son in all modern genetic models.

0:43:08Keith Humphreysneeds contextmoderate

Lab studies demonstrate that cannabis users, even experienced ones, are surprisingly poor at accurately judging the potency or strength of different cannabis products.

"In fact, people are surprisingly bad, even experienced pot smokers, at judging in lab studies of like how strong different cannabis is." (said at 0:43:08)

Studies evaluating cannabis users' ability to estimate THC concentration and product potency find that users are generally poor at judging actual potency, relying heavily on product type or crude sensory cues rather than actual cannabinoid concentrations. However, more frequent or daily users estimate potency significantly better than occasional/recreational users (e.g., daily users' ratings correlate moderately with actual THC concentrations, partial r = 0.381, compared to r = 0.052 in recreational users), qualifying the claim that experienced smokers are equally poor at judging strength.

0:43:36Keith Humphreysneeds contextlow

Cannabis products in legal markets frequently have unevenly blended THC concentrations within individual edible units.

"The other thing that is true is that a lot of these products are not well made or they're not up to like the standards of like you would have a cookie. You would never open up a bag of chocolate chip cookies in the United States and find all the chocolate chips at one end and just dough in the rest. But that does happen with cannabis products in legal markets." (said at 0:43:36)

Research on commercially available legal and medical cannabis edibles frequently demonstrates significant quality-control and manufacturing standardization issues, leading to widespread discrepancies between advertised and actual cannabinoid content across packages. While the food matrix and manufacturing methods can lead to uneven cannabinoid distribution (intra-unit non-homogeneity) that prompted states to enact homogeneity testing regulations, characterizing products as frequently having extreme intra-unit pooling (e.g., all THC at one end of a cookie) describes a known manufacturing defect rather than the typical pattern, which is primarily characterized by broad package-level label inaccuracy and batch variability.

1:12:48Andrew Huberman (host)needs contextmoderate

In clinical trials for major depression that has not responded to other treatments, high-dose psilocybin-assisted psychotherapy yields significant relief or remission in 60% to 70% of patients.

"that it's been somewhere between 60 and 70% of people who go into that sort of thing with major depression that hasn't been resolved by other approaches um get either significant relief or uh full remission after two full versions of what I just described at fairly high dosages." (said at 1:12:48)

The speaker accurately describes findings from landmark clinical trials evaluating two-dose psilocybin-assisted psychotherapy protocols (such as Carhart-Harris et al., 2016 in treatment-resistant depression and Davis et al., 2021 in major depressive disorder), where overall clinical response (significant relief) or remission rates were reported at approximately 67% to 71%. Systematic reviews and meta-analyses of randomized controlled trials confirm that standard/high-dose psilocybin-assisted therapy produces substantial, statistically significant increases in response (RR ~2.3-3.4) and remission (RR ~3.4-3.7) compared to controls. However, context is required: the highest response and remission rates (60–70%) were primarily observed in early open-label or waitlist-controlled trials, whereas larger randomized double-blind trials specifically in treatment-resistant depression (e.g., Goodwin et al., 2022) found more modest response (~37%) and remission (~29%) rates.

1:24:34Keith Humphreysneeds contexthigh

Ketamine is FDA-approved for treatment-resistant depression.

"yes, it is FDA-approved for treatment-resistant depression. So it is approved." (said at 1:24:34)

Generic racemic ketamine (typically administered intravenously or intramuscularly) is not FDA-approved for treatment-resistant depression (TRD) and is used off-label for psychiatric conditions. However, its S-enantiomer, esketamine (Spravato nasal spray), received FDA approval in 2019 for use in conjunction with an oral antidepressant for adults with TRD.

1:36:40Andrew Huberman (host)needs contextmoderate

Approximately 90 percent of the adult world consumes caffeine.

"I think 90% of the world uses caffeine—adult world uses caffeine." (said at 1:36:40)

Caffeine is universally recognized in biomedical literature as the most widely consumed central nervous system stimulant and psychoactive substance worldwide. Population surveys (such as NHANES in the United States and similar epidemiological studies in North America and Europe) consistently show that approximately 85% to 90% of adults regularly consume caffeinated beverages or foods. However, globally, epidemiological estimates commonly cite that approximately 80% of the world's population consumes caffeine daily, with figures reaching 85–90% specifically in adult populations in North America and Western countries.

3:18:45Keith Humphreysneeds contextmoderate

Men consume higher volumes of addictive substances across all global cultures and are overrepresented in all major addictions.

"Men are larger consumers of addictive substances in every culture on earth and are overrepresented in all the major addictions." (said at 3:18:45)

Epidemiological surveillance data from the Global Burden of Disease (GBD) studies and global surveys broadly support the observation that men have significantly higher rates of substance use and substance use disorders (including alcohol and illicit drug use disorders) across virtually all world regions. However, the absolute claim that men consume higher volumes across 'every culture on earth' and are overrepresented in 'all the major addictions' requires context/qualification: while true for the major categories of alcohol, cannabis, opioids, and stimulants, epidemiological data consistently show that certain classes of addictive substances—most notably prescription sedatives, tranquilizers/benzodiazepines, and non-medical prescription analgesics in several high-income countries—show equal or higher rates of misuse and dependence among women.

65 Supported by research
0:07:19Keith Humphreyssupportedmoderate

Adoption studies demonstrate that children born to parents with alcohol addiction have a significantly higher likelihood of developing an alcohol problem, even when raised by teetotaler adoptive parents.

"You know, we look at studies where kids were adopted out of families with parents who, you know, were addicted to alcohol—much higher likelihood of developing an alcohol problem, even if they were raised by teetotalers, for example." (said at 0:07:19)

Classic cross-fostering adoption studies (such as the Danish adoption studies by Goodwin et al. and the Stockholm Adoption Study by Cloninger, Bohman, and Sigvardsson) examined children of biological parents with alcohol use disorder adopted into non-alcoholic/teetotaler homes. They found that biological children of parents with alcoholism had a significantly increased risk (3- to 6-fold) of developing alcoholism compared to controls, even when raised in adoptive environments free of parental alcohol problems (such as in Type II/male-limited alcoholism, where genetic background predicted outcome regardless of adoptive environment).

0:07:39Keith Humphreyssupportedmoderate

The shared genetic heritability across most addictive substances is estimated to be approximately 0.3 to 0.5.

"How big is that? It varies across studies, it varies across substances, but it's large. It might be like, you know, 0.3, 0.4, 0.5 for most of them." (said at 0:07:39)

Extensive twin, adoption, and family studies demonstrate that the heritability of substance use disorders (including alcohol, nicotine, cannabis, cocaine, and opioids) typically ranges between 0.30 and 0.60 (30% to 60%), aligning closely with the stated estimate of 0.3 to 0.5. Meta-analyses of twin and adoption studies report heritability estimates of approximately 0.49 (49%) for alcohol use disorders and 0.51 to 0.59 (51-59%) for problematic cannabis use.

0:07:59Keith Humphreyssupportedhigh

Many Han Chinese individuals lack or have low levels of the enzyme that breaks down acetaldehyde into acetic acid during alcohol metabolism, making alcohol consumption less pleasant and specifically lowering their risk for alcoholism.

"So here's an example of a specific one: if you are born into a group like Han Chinese are and you lack the enzyme or don't have much of a particular enzyme that is used to metabolize alcohol, it is just a less enjoyable experience to drink. You know, you can't break down acetaldehyde into acetic acid and all that sort of thing. And so that one would lower your risk for—not anything else, but at least specifically for alcohol." (said at 0:07:59)

Extensive genetic and pharmacokinetic research confirms that a substantial proportion of Han Chinese and East Asian individuals carry the ALDH2*2 (or ALDH2*504Lys) polymorphism. This variant encodes an inactive or deficient mitochondrial aldehyde dehydrogenase (ALDH2), the enzyme responsible for converting acetaldehyde into acetic acid (acetate). Accumulation of acetaldehyde following alcohol ingestion causes facial flushing, tachycardia, and aversive subjective symptoms (general discomfort/unpleasantness), which provides strong genetic protection (partial in heterozygotes, nearly complete in homozygotes) against alcohol dependence and alcoholism.

0:21:56Keith Humphreyssupportedmoderate

Approximately 10% of the population in the United States consumes about 50% of all alcohol sold.

"because something like what, 10% of our country drinks about half the alcohol. Right, United States." (said at 0:21:56)

The claim is supported by national survey data on the distribution of alcohol consumption in the United States. Analysis from the National Alcohol Survey (Greenfield & Rogers, 2007) found that the top 10% of drinkers account for approximately 55.3% of total alcohol consumed in the U.S.

0:23:20Keith Humphreyssupportedhigh

Following cannabis legalization, cannabis use among youth has changed only slightly, with the main growth in use occurring among adults.

"With the legalization of cannabis, we certainly have seen a lot more use and a lot stronger products, but youth use really has only changed pretty slightly. So the growth has really been among adults, including adults who probably stopped at some point and have now gone back in later life to using cannabis." (said at 0:23:20)

Substantial epidemiological surveillance data and systematic reviews confirm that recreational cannabis legalization has been accompanied by significant increases in cannabis use among adults (as well as increased product potency), while cannabis use among adolescents and youth has remained largely flat or changed only slightly.

0:25:51Keith Humphreyssupportedmoderate

Studies establishing a J-shaped curve showing lower mortality in low-drinking groups compared to non-drinkers were confounded by including former problem drinkers with pre-existing health damage in the non-drinking reference groups.

"When they would look at studies and say, "Well, look, you know, the non-drinking group have higher mortality than the low-drinking group," and the famous called the J-shaped curve, you know, like that. Problem is non-drinkers include people who are like in Alcoholics Anonymous. That's why they don't drink. They had a, you know, a wretched experience with alcohol. And so, you know, they've had different kinds of damage to their bodies. Maybe their health isn't as good." (said at 0:25:51)

Large systematic reviews and meta-analyses confirm the speaker's claim. Historical observational studies establishing the apparent J-shaped curve (where low-volume drinkers appeared to have lower mortality than non-drinkers) largely failed to distinguish lifetime abstainers from former drinkers who stopped drinking due to ill health or prior alcohol abuse (the 'sick quitter' or 'abstainer bias'). When meta-analyses control for this confounding and exclude former drinkers from reference categories, the apparent protective effect of low-volume alcohol consumption on all-cause mortality disappears.

0:26:35Keith Humphreyssupportedmoderate

Any cardiovascular benefits associated with low alcohol intake are smaller than the associated increase in cancer risk, resulting in no net reduction in mortality.

"There might be some cardiac benefit, okay? But, you know, we don't get to, you know, live our lives as single organs. We have a whole body. You have to weigh that if that is true. And it is wobbly. If that's true, it's smaller than the cancer risk. So your net is you're not going to get any mortality gain from—mortality reduction from drinking alcohol." (said at 0:26:35)

Large systematic analyses and meta-analyses, notably the Global Burden of Diseases (GBD) 2016 study and multi-cohort analyses, show that while low-to-moderate alcohol consumption may exhibit an inverse association with specific cardiovascular outcomes (such as myocardial infarction), these potential benefits are offset by increased risks of cancer (including breast, colorectal, and aerodigestive cancers), stroke, and other health conditions. As a result, the level of alcohol consumption that minimizes all-cause mortality and overall health loss across the entire body is zero drinks per week.

0:27:01Keith Humphreyssupportedmoderate

Consuming two alcoholic drinks per week carries only a very small increase in health risk.

"If you have two drinks a week—and by a drink I mean like a 12-ounce beer, a 1-ounce shot, or a 4-ounce glass of wine—you have slightly higher risk, but it is very, very, very small." (said at 0:27:01)

Large systematic reviews and meta-analyses of prospective cohort studies confirm that consuming two standard alcoholic drinks per week (approximately 3 to 4 grams of ethanol per day) is associated with little to no detectable excess mortality or disease risk compared with lifetime abstention. A 2023 meta-analysis of 107 cohort studies encompassing over 4.8 million individuals found no statistically significant difference in all-cause mortality among occasional and low-volume drinkers (RR 0.96, 95% CI 0.86–1.06) after adjusting for abstainer biases. Comprehensive global burden models (GBD 2020) and national public health guidelines similarly classify 1 to 2 standard drinks per week in the lowest tier of risk.

0:35:49Keith Humphreyssupportedhigh

Alcohol acts as an anxiolytic.

"what I think most people would say is just the anxiety is intense for some people and alcohol is anxiolytic, right?" (said at 0:35:49)

Alcohol (ethanol) is well-established pharmacologically and clinically as an anxiolytic and central nervous system depressant. It acts primarily as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission in brain regions involved in anxiety and stress response (such as the amygdala).

0:38:24Keith Humphreyssupportedmoderate

In the 1980s and 1990s, average cannabis THC content was approximately 3% to 5%.

"So if you go back to the '80s and '90s, when, as you mentioned, it was illegal everywhere, the THC content—that's the principal intoxicant—would be, you know, 3, 4, 5%, something like that on average." (said at 0:38:24)

Analyses from the University of Mississippi / NIDA Potency Monitoring Project and systematic review data show that average THC concentrations in confiscated cannabis in the United States during the 1980s and 1990s were consistently in the 1.5% to 5% range (rising from under 1.5% to ~3.3% in the early-to-mid 1980s, fluctuating around 3% through 1992, and reaching ~4.0% to 4.5% by the late 1990s).

0:38:40Keith Humphreyssupportedmoderate

Studies of legal cannabis sales show that the average product has a THC content of about 20%.

"And now studies of legal sales show the average product is about 20%." (said at 0:38:40)

Studies analyzing sales data from legal retail cannabis markets support the claim. For example, an analysis of over 30 million retail cannabis purchases in Washington State's legal market found that the average THC concentration for cannabis flower (which accounted for approximately two-thirds of total sales) was 20.6%, while cannabis extracts averaged 68.7% THC. Studies across other North American legal markets similarly report average THC concentrations for legal retail flower products in the ~16–21% range.

0:38:47Keith Humphreyssupportedhigh

Data compiled by Jonathan Caulkins shows that about 42% of people who use cannabis use it every day or almost every day.

"Jonathan Caulkins pulled together a lot of really interesting data that got a lot of play, and it showed that about 40—I think it's 42% of people who use cannabis use it every day or almost every day." (said at 0:38:47)

A 2024 study by Jonathan Caulkins analyzing US National Survey on Drug Use and Health (NSDUH) data from 1979 to 2022 found that in 2022, 42.3% of past-month cannabis consumers reported daily or near-daily use, directly supporting the speaker's claim.

0:39:20Keith Humphreyssupportedhigh

The potency difference between a coca leaf and purified cocaine is approximately 65 times.

"Well, coincidentally, it is also the potency difference between a coca leaf and cocaine. That is 65 times, too." (said at 0:39:20)

Chemical analyses of coca leaves (*Erythroxylum coca*) show that they typically contain between 0.5% and 1.5% cocaine alkaloid by dry weight (e.g., approximately 0.70% to 0.95% or ~7.7–9.5 mg/g). Purified cocaine (100% cocaine base or hydrochloride) is therefore roughly 65 to 140 times more concentrated/potent by weight than the raw dry leaf, making the 65-fold figure a well-supported estimate.

0:40:20Keith Humphreyssupportedhigh

CBD is used as a medical treatment for pediatric seizure disorders.

"We do have some out of the CBD, which is the non-intoxicating part, is a medication that is used in seizure disorders in kids." (said at 0:40:20)

The speaker's claim that cannabidiol (CBD) is formulated as a medication used to treat seizure disorders in children is fully supported. A purified, plant-derived CBD oral solution (Epidiolex) was approved by the US FDA for the treatment of seizures associated with severe childhood-onset epilepsies, including Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, based on multiple rigorous phase 3 randomized controlled clinical trials.

0:40:37Keith Humphreyssupportedmoderate

Around 2020, the United States Congress changed laws regulating cannabis research to make conducting studies simpler.

"About 2020, Congress changed the way research works, so it's a lot simpler to do it." (said at 0:40:37)

The speaker's statement is supported. Around that time (enacted in late 2022 as the Medical Marijuana and Cannabidiol Research Expansion Act, H.R. 8454 / S.253), the United States Congress passed legislation aimed at streamlining and expanding scientific research on cannabis and cannabidiol, easing regulatory burdens for researchers studying cannabis.

0:44:05Keith Humphreyssupportedmoderate

Swedish military registry cohort studies found that men who used cannabis during their teenage years had higher rates of psychotic disorders in adulthood.

"in the old studies, they would be men who had used cannabis in teen years and then they would have higher rates of psychotic disorders in adult. These were studies based on like Swedish registries because everybody has to register for the military, and they would track people." (said at 0:44:05)

The speaker accurately describes the seminal Swedish conscript cohort studies (e.g., Andréasson et al., 1987; Zammit et al., 2002). These studies followed tens of thousands of Swedish males conscripted at ages 18–20 and linked self-reported cannabis use to nationwide hospital discharge registries. They found a dose-dependent increased risk of developing schizophrenia and other psychotic disorders in adulthood among those who used cannabis in adolescence, an association that persisted after adjusting for other substance use and baseline psychiatric indicators.

0:46:40Keith Humphreyssupportedhigh

The first psychotic break typically occurs around ages 18 to 21.

"during that period of brain development before people get their first psychotic break, which tends to be around 18, 19, 20, 21." (said at 0:46:40)

A large-scale global meta-analysis of epidemiological studies (Solmi et al., 2022; PMID 34079068) found that the peak age at onset for schizophrenia-spectrum disorders and primary psychotic states is 20.5 years, aligning directly with the speaker's stated range of 18 to 21 years. While the median age of onset across all psychotic disorders extends into the mid-twenties (median = 25 years, interquartile range = 20–34 years), peak incidence occurs in late adolescence and early adulthood.

0:49:00Keith Humphreyssupportedmoderate

Regular cannabis use impairs short-term memory, concentration, and the ability to keep track of details.

"But it does with regular use undermine certain things that you need to succeed in the modern world, like short-term memory and concentration and being able to keep track of details." (said at 0:49:00)

Extensive meta-analytic and systematic review literature confirms that regular, long-term, or chronic cannabis use is associated with small-to-moderate deficits across several cognitive domains, including short-term and working memory, attention/concentration, and executive functioning (such as cognitive flexibility and keeping track of complex information). While acute intoxication produces the most pronounced impairments, residual deficits have been consistently observed in regular and chronic users.

0:56:23Keith Humphreyssupportedhigh

Alcohol consumption causes approximately 150,000 deaths in the United States each year.

"Well, alcohol also kills, you know, about 150,000 Americans a year." (said at 0:56:23)

Epidemiological estimates from the U.S. Centers for Disease Control and Prevention (CDC) and population health studies indicate that excessive alcohol consumption causes between 95,000 and nearly 180,000 deaths annually in the United States (averaging approximately 140,000 to 178,000 in recent reporting periods and roughly 95,000 to 125,000 in earlier adjusted estimates). The speaker's figure of 'about 150,000 Americans a year' is an accurate estimate of annual alcohol-attributable mortality.

0:56:35Keith Humphreyssupportedhigh

Drunk driving causes approximately 10,000 deaths per year in the United States.

"You know, we should legalize drunk driving because, you know, that only kills 10,000 people." (said at 0:56:35)

Surveillance data from the Centers for Disease Control and Prevention (CDC) and the National Highway Traffic Safety Administration (NHTSA) confirm that alcohol-impaired driving (defined as a driver having a blood alcohol concentration of 0.08 g/dL or greater) accounts for approximately 10,000 to 10,500 deaths annually in the United States.

0:40:20Keith Humphreyssupportedhigh

The human endocannabinoid receptor system is distributed throughout both the brain and the peripheral body.

"The cannabinoid receptor system evolutionarily is one of the oldest in the history of Homo sapiens. It is both in the brain, but it's also in the body." (said at 0:40:20)

The claim accurately describes the established anatomical distribution of the endocannabinoid receptor system. Cannabinoid receptor type 1 (CB1) is abundantly expressed throughout the central nervous system (such as the cortex, hippocampus, cerebellum, and basal ganglia) as well as peripheral tissues (including adipose tissue, liver, gastrointestinal tract, pancreas, skeletal muscle, and cardiovascular system). Cannabinoid receptor type 2 (CB2) is predominantly distributed across the peripheral immune system, lymphoid organs, and immune cells.

0:46:28Keith Humphreyssupportedmoderate

Addictions overwhelmingly originate when individuals begin substance use during their teenage years or late childhood.

"And so a lot of these effects, the worst things are going to be because people start when they're in teen or late single digits. That's where addictions overwhelmingly start." (said at 0:46:28)

Epidemiological and longitudinal cohort data consistently demonstrate that substance use initiation and the onset of substance use disorders overwhelmingly occur during adolescence and young adulthood. In large-scale cross-national surveys across 29 countries, the conditional probability of first onset of mental and substance use disorders peaked at approximately 15 years of age, with median onset occurring between 19 and 20 years. Furthermore, longitudinal data show that initiating substance use in early adolescence (e.g., at or before age 12 to 14) is strongly associated with substantially elevated risks of developing hazardous substance use and substance use disorders compared to later initiation.

0:57:10Keith Humphreyssupportedmoderate

Even heavy substance users are sensitive to price and reduce consumption in response to taxation.

"That's why taxes—to which people are people, even heavy users, respond to price. Um, you know, that's a really important tool to regulate them." (said at 0:57:10)

A major meta-analysis of the economics and addiction literature confirms that substance consumption among heavy users is sensitive to price and taxation, though their demand is generally more inelastic (smaller magnitude of responsiveness) than that of moderate users. A meta-analysis of 112 studies found that higher alcohol taxes and prices significantly reduce heavy drinking with a mean elasticity of -0.28 (p < 0.01).

1:05:08Keith Humphreyssupportedmoderate

A large proportion of problem gamblers are also problem drinkers and addicted to cigarettes.

"And and a huge number of people, problem gamblers, are problem drinkers and and also are addicted to cigarettes." (said at 1:05:08)

Large-scale epidemiological studies and systematic reviews consistently demonstrate high rates of comorbidity between problem/pathological gambling, alcohol use disorders, and nicotine dependence. A meta-analysis of population-representative surveys (Lorains et al., 2011) found that 60.1% of problem and pathological gamblers met criteria for nicotine dependence and 57.5% met criteria for a substance use disorder. Similarly, data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, n=43,093) found that 73.2% of individuals with lifetime pathological gambling had a lifetime alcohol use disorder and 60.4% had nicotine dependence.

1:06:09Keith Humphreyssupportedmoderate

Cannabis decriminalization policies do not substantially alter overall rates of cannabis use.

"So, decriminalization is about the user, and that's to say, look, we're not going to punish you for using pot. Okay? And that is a pretty popular It's always It's been a popular policy for a long time and doesn't seem to really affect use that much. You know, maybe a little bit, but not a lot." (said at 1:06:09)

Evidence from evaluations of cannabis decriminalization policies (removing criminal penalties for simple possession/use without establishing a legal commercial market) in the United States, Australia, and Europe indicates that decriminalization has had minimal or negligible impacts on population-level prevalence or rates of cannabis use.

1:07:12Keith Humphreyssupportedmoderate

Initiating use of any substance as an adolescent increases the likelihood of progressing to other substances.

"So, all drugs are gateway drugs. The the lie in that was that, you know, cannabis had some unique role um, you know, that was going to lead you to use heroin. But the truth is anything, like, you know, if you're a teenager and you start smoking, or you start drinking, or you start uh, you know, using cannabis, or or, you know, stealing prescription opioids from your parents or whatever, that will increase your likelihood of progressing to other substances" (said at 1:07:12)

Large longitudinal and epidemiological cohort studies show that initiating any substance during adolescence (including alcohol, tobacco, cannabis, inhalants, or prescription medications) is associated with an increased risk and probability of progressing to other subsequent substances. Furthermore, epidemiological analyses indicate this pattern is not unique to cannabis but is broadly shared across early substance initiation, fitting a generalized liability or common cause model of adolescent substance progression.

1:11:48Keith Humphreyssupportedmoderate

There is no evidence that people get addicted to psilocybin or LSD, and their abuse potential is extremely slight.

"The one thing we do know good, though, keeping on the topic of addiction, is thankfully, um, you know, there's no evidence that people get addicted to psilocybin or uh to LSD. If they have abuse potential, it's extremely, extremely slight." (said at 1:11:48)

Extensive preclinical, clinical, and epidemiological evidence indicates that classic 5-HT2A agonist psychedelics, including psilocybin and LSD, do not produce compulsive drug-seeking behavior, physical dependence, or withdrawal syndromes. They demonstrate minimal reinforcing efficacy in animal self-administration models, and their overall abuse liability and dependence potential are considered exceptionally low compared to classic drugs of abuse.

1:24:34Keith Humphreyssupportedmoderate

Ketamine use causes severe bladder damage, resulting in severe urological dysfunction in young users.

"And then you do have the other problem: it is addictive. And so we have a lot of people getting addicted, and then also the bladder damage you get from it. You get young people with sort of 60-year-old bladders from ketamine. And most urologists have seen this now. It's like, why is someone at 25 coming in with this? It's like, because their bladder has been damaged by ketamine." (said at 1:24:34)

Ketamine-induced uropathy (or ketamine-associated ulcerative cystitis) is a well-established clinical syndrome primarily affecting young chronic or recreational users. Systematic reviews and clinical studies confirm that repeated ketamine exposure causes severe lower urinary tract symptoms, urothelial damage, persistent inflammation, marked bladder wall fibrosis, reduced bladder capacity (contracted bladder), and potentially upper urinary tract sequelae such as hydronephrosis and ureteral stenosis.

1:26:06Keith Humphreyssupportedhigh

Repetitive transcranial magnetic stimulation (rTMS) is FDA-approved for depression and is covered by Medicare.

"I mean, rTMS for depression is approved, and so you can get it at clinics that have this technology. These are big, expensive machines, so I'm sure there's lots of places where they're not local. But, yeah, it's covered. I think Medicare actually covers it." (said at 1:26:06)

Repetitive transcranial magnetic stimulation (rTMS) is approved/cleared for treating depression (specifically treatment-resistant major depressive disorder) in the United States and has established coverage under Medicare fee-for-service and commercial plans, as demonstrated in observational claims analyses of Medicare datasets and clinical consensus guidelines.

1:27:13Keith Humphreyssupportedmoderate

In rTMS clinical trials, sham stimulation effectively blinds participants so they cannot guess whether they received active or sham treatment.

"Unlike with psychedelics, you really can fool people that they're getting rTMS. You know, it's always tough to interpret psychedelic trials because everybody knows when they've gotten the psychedelic drug. The people in the control experiment know they're in the control experiment. That's correct. But not true in rTMS. You can put these coils on the head—I've actually tried it—and it feels like something's happening and it's just a sham. And when you ask people again, guess which condition they're in, they can't guess." (said at 1:27:13)

Meta-analytic and systematic review evidence supports the claim that sham rTMS protocols achieve acceptable blinding integrity. In a systematic review and meta-analysis of randomized sham-controlled trials in major depression (Berlim et al., 2013), participants in active and sham rTMS groups did not differ significantly in their ability to correctly guess their treatment allocation at the end of the trial (52% vs. 59% for high-frequency rTMS, and 63.3% vs. 57.5% for bilateral rTMS, both hovering near chance level). Similarly, a systematic review by Broadbent et al. (2011) found no significant difference in guessing accuracy between active and sham groups across evaluated trials.

1:30:09Keith Humphreyssupportedhigh

SSRIs carry a non-zero risk of increasing suicidal behavior or ideation in adolescents.

"There is some worry about adolescents on SSRIs. This has been a really hard-fought, debated issue for years. And it's tough, because depression, of course, raises suicide risk, right? So by definition, if someone's getting an SSRI, they already have some risk present. I think there's some legitimate worry with teenagers. I would say it's non-zero" (said at 1:30:09)

Comprehensive meta-analyses of pediatric randomized placebo-controlled trials conducted for the US FDA found a statistically significant, non-zero increase in suicidal ideation and behavior among children and adolescents taking SSRIs and other second-generation antidepressants compared to placebo (overall relative risk ~1.66 to 1.95; absolute risk difference ~0.7% to 2.0%), which prompted the FDA's black-box warning. Across clinical trials, no completed suicides were observed, but the elevated risk of suicidal ideation and attempts is well-documented.

1:30:39Andrew Huberman (host)supportedlow

Some patients experience persistent sexual dysfunction even after discontinuing finasteride treatment for hair loss.

"We also see this with finasteride, which was used to treat baldness. And our colleague Mike Eisenberg came on here and said, look, the data aren't really there, but I hear from a lot of young guys who were given these anti-hair-loss drugs and they come off the drugs and they're still experiencing debilitating sexual side effects." (said at 1:30:39)

Observational studies, case series, and pharmacovigilance reports have documented that a subset of men treated with finasteride for androgenetic alopecia report persistent sexual dysfunction (such as erectile dysfunction, decreased libido, and ejaculatory disorders) that continues after drug cessation—a phenomenon often described as post-finasteride syndrome (PFS). The certainty of evidence is low because data primarily come from cross-sectional, observational, and self-reported cohorts rather than randomized prospective trials, which aligns with the speaker's qualification that large-scale trial data remain limited.

1:13:40Andrew Huberman (host)supportedmoderate

MDMA use is characteristically followed by a noticeable drop in mood approximately two days after consumption.

"And this, by the way, is separate from the very well-known trough that comes 2 days after MDMA use. We could talk about that, but um you get high and then there's a low, you know, very well explained." (said at 1:13:40)

A drop in mood occurring 2 to 3 days following recreational MDMA/ecstasy use (often colloquially called the 'midweek blues', 'suicide Tuesday', or 'comedown') is well-documented in observational and naturalistic studies. Research demonstrates significant increases in depression, negative affect, and reduced mental well-being in the days following weekend MDMA consumption, mediated partly by transient monoaminergic (serotonin) depletion, sleep disruption, and polydrug use. While recent clinical trials using pharmaceutical-grade MDMA in controlled therapeutic settings report minimal to no post-acute mood drop, the recreational phenomenon referenced by the speaker is empirically supported.

1:30:39Andrew Huberman (host)supportedmoderate

Some individuals experience persistent sexual and mood-related side effects that do not resolve even after discontinuing SSRI antidepressants.

"And there's a constellation of mainly sexual side effects and mood-related side effects that don't seem to resolve even after coming off. We also see this with finasteride" (said at 1:30:39)

A well-documented phenomenon termed post-SSRI sexual dysfunction (PSSD)—as well as post-finasteride syndrome (PFS)—is recognized in the medical literature and regulatory pharmacovigilance databases. In a subset of individuals, sexual side effects (such as genital anesthesia, erectile dysfunction, decreased libido, and orgasmic anhedonia) and neuropsychiatric/mood-related symptoms (such as emotional blunting, apathy, and anhedonia) persist long after discontinuing SSRIs or finasteride.

1:32:21Keith Humphreyssupportedhigh

Clinical trials for opioid approval in pain management are typically 9 to 12 weeks in duration.

"I mean, if you look at like the typical trial for opioids and pain, it's like 9 weeks or 12 weeks." (said at 1:32:21)

Extensive systematic reviews and meta-analyses of randomized controlled trials for opioids in chronic non-cancer pain demonstrate that the vast majority of efficacy trials are short- to intermediate-term, typically lasting between 6 and 12 (or up to 16) weeks (FDA regulatory trials for chronic pain indications standardly require 12 weeks of double-blind treatment). Placebo-controlled trials evaluating opioids beyond 12 to 16 weeks are exceedingly rare.

1:33:20Andrew Huberman (host)supportedmoderate

An ibogaine psychedelic experience lasts approximately 22 hours and requires heart rate monitoring.

"It's a 22-hour-long psychedelic experience. You have to be heart rate monitored." (said at 1:33:20)

The statement accurately reflects clinical and pharmacological literature regarding ibogaine. The acute subjective and visionary (oneiric/introspective) effects of ibogaine characteristically persist for approximately 20 to 36 hours (consistent with the stated 22-hour timeframe). Furthermore, because ibogaine blocks hERG potassium channels and causes dose-dependent QTc interval prolongation, bradycardia, and risk of life-threatening ventricular arrhythmias (such as Torsades de Pointes and cardiac arrest), standard safety protocols mandate continuous cardiovascular and electrocardiographic monitoring during administration.

1:34:53Keith Humphreyssupportedlow

Dr. Nolan Williams conducted an open-label trial with no control group testing ibogaine in veterans, including pre- and post-treatment neuroimaging.

"he did the important thing: he imaged people, neuroimaged them before and afterwards, and he was able to see a lot of these changes... The thing to say is this is an open-label trial with no control group, so that's what we have so far." (said at 1:34:53)

Dr. Nolan Williams and colleagues at Stanford conducted an open-label, prospective observational study without a control group evaluating a magnesium-ibogaine protocol (MISTIC, NCT04313712) in 30 Special Operations Forces military veterans with traumatic brain injury and co-occurring conditions. The study incorporated multimodal pre- and post-treatment neuroimaging (including structural MRI, functional MRI, and arterial spin labeling), demonstrating post-treatment changes in cortical thickness, predicted brain age, cerebral blood flow, and functional connectivity.

1:37:45Keith Humphreyssupportedhigh

There are no pharmacotherapies with proven efficacy for treating crack cocaine or stimulant addiction.

"The treatment offering to people who were addicted to crack cocaine then in the late '80s is not very different from what it is today, which is almost 40 years later: no pharmacotherapy at all, nothing, no evidence of anything that works in pharmacotherapy" (said at 1:37:45)

Extensive systematic reviews, meta-analyses, and Cochrane reviews confirm that there are currently no approved or clinically proven pharmacotherapies for cocaine or crack cocaine use disorder. Although numerous drug classes have been tested across hundreds of randomized controlled trials (including antidepressants, antipsychotics, anticonvulsants, dopamine agonists, and psychostimulants), none have demonstrated robust, consistent efficacy for achieving sustained abstinence or reducing cocaine use, leaving psychosocial interventions (such as contingency management) as the only established evidence-based treatment.

1:38:45Keith Humphreyssupportedhigh

Contingency management using escalating monetary rewards for negative urinalysis results is effective in reducing stimulant use.

"The only thing that seems to work is contingency management, which are these things where Steve Higgins, I think, was the first person to do this... He started experimenting with people addicted to cocaine, saying, 'Well, you're coming into treatment. How about tomorrow we'll do a urinalysis when you come in, and if it's a negative urinalysis, the first day we'll give you two bucks, and the day after we'll give you four bucks, the day after we give you eight bucks, the day after give you 16 bucks.' And he found out people stopped." (said at 1:38:45)

The speaker's claim accurately describes the origins and efficacy of contingency management for stimulant use disorder. Stephen Higgins and colleagues pioneered voucher-based contingency management in the 1990s for cocaine dependence, which utilizes escalating monetary voucher reinforcement contingent on consecutive drug-negative urinalysis results. Extensive randomized controlled trials and systematic reviews/meta-analyses have confirmed that contingency management is highly effective in promoting continuous abstinence and reducing stimulant use (including cocaine and amphetamines), showing robust medium-to-large effect sizes during treatment.

1:43:31Andrew Huberman (host)supportedmoderate

Treating ADHD with medication reduces the risk of subsequent substance abuse compared to leaving ADHD untreated.

"his claim is that non-treated ADHD poses a much greater risk for addiction than treating ADHD with substances that in non-ADHD folks are addictive. In other words, if a kid or adult has ADHD and doesn't medicate, they're at much greater risk of abusing drugs. Um if you do medicate, they're at much lower risk because it lowers the impulsivity." (said at 1:43:31)

Extensive longitudinal and within-individual pharmacoepidemiologic studies consistently demonstrate that pharmacological treatment for ADHD is associated with a reduced risk of concurrent and subsequent substance misuse or substance-related events compared to periods of non-treatment. A target-trial emulation study involving 148,581 individuals with ADHD found that initiating medication reduced the rate of first-occurrence substance misuse (adjusted incidence rate ratio 0.85, 95% CI 0.83-0.87) and recurrent events (IRR 0.75, 95% CI 0.72-0.78). Similarly, a nationwide commercial claims study of nearly 3 million patients found a 31% to 35% lower concurrent risk of substance-related emergency events and reduced long-term risk during and after medication periods.

1:44:05Keith Humphreyssupportedhigh

There is a very high prevalence of ADHD among adults who are addicted to alcohol.

"There is a very high rate of ADHD among people, you know, in adulthood you see are alcohol-addicted" (said at 1:44:05)

Systematic reviews and meta-analyses consistently show a high prevalence of ADHD among adults with substance and alcohol use disorders. In general adult populations, ADHD prevalence is estimated at approximately 2.5% to 5%, whereas meta-analyses of clinical populations with substance use disorders—including alcohol dependence—report comorbid ADHD rates of approximately 22% to 23% (roughly one in four to five individuals).

1:45:00Andrew Huberman (host)supportedlow

Oral nicotine accelerates skin aging due to vasoconstriction in the skin.

"it definitely ages skin faster because of the vasoconstriction in the skin, so it makes you look older even though you're not smoking it, the oral nicotine." (said at 1:45:00)

Nicotine itself, independent of cigarette smoke inhalation, acts on nicotinic acetylcholine receptors present on cutaneous blood vessels, keratinocytes, and fibroblasts. Pharmacological and dermatological evidence demonstrates that systemic nicotine causes cutaneous vasoconstriction, impairs microvascular perfusion, delays wound healing, and accelerates skin aging. However, direct clinical trials specifically quantifying long-term facial aging from modern oral nicotine formulations (e.g., pouches) remain limited, relying primarily on mechanistic and observational nicotine data.

1:45:37Keith Humphreyssupportedmoderate

Consuming all the nicotine contained in a single carton of cigarettes is lethal.

"If you if you consumed all the nicotine in a carton of cigarettes, it would kill you." (said at 1:45:37)

A standard carton of cigarettes contains 10 packs (200 cigarettes). An unburned cigarette typically contains 10–15 mg of nicotine, making the total nicotine content of a carton approximately 2,000 to 3,000 mg. In human toxicology, the estimated oral lowest lethal dose (LDLO) in adults is 1–14 mg/kg (roughly 70 to 1,000 mg for an adult), and acute ingestions of 100 mg or more are considered potentially lethal. Consuming all the nicotine present in a full carton exceeds the lethal threshold by a wide margin.

1:46:30Keith Humphreyssupportedhigh

Sleeplessness is a clinical symptom of cannabis withdrawal.

"one sign of cannabis withdrawal is sleeplessness." (said at 1:46:30)

Sleep disturbance/sleeplessness (insomnia) is an established, core diagnostic symptom of Cannabis Withdrawal Syndrome (CWS) defined in both the DSM-5 and ICD-11. Epidemiological studies and systematic reviews confirm that sleep difficulty is among the most commonly reported clinical signs of cannabis withdrawal, occurring in over two-thirds of individuals meeting criteria for cannabis withdrawal.

1:50:20Keith Humphreyssupportedmoderate

Surveys indicate that approximately 24 million Americans are in recovery from substance addiction.

"surveys give something like 24 million Americans are in recovery." (said at 1:50:20)

The claim accurately reflects findings from major national survey research in the United States. In the landmark National Recovery Study (Kelly et al., 2017/2018), a nationally representative probability-based sample of US adults (N = 39,809 screened; n = 1,995 to 2,002 individuals resolving significant substance use problems) estimated that approximately 9% of the US adult population—equating to roughly 22.3 to 24 million Americans—have resolved a significant alcohol or other drug problem / are in recovery. Similar figures are also reported in SAMHSA national survey analyses.

1:44:33Andrew Huberman (host)supportedhigh

Oral nicotine use contributes to the development or worsening of gum disease.

"Then the oral health folks tell me that it's bad for gum disease." (said at 1:44:33)

The host's statement that oral health professionals consider nicotine and tobacco products detrimental to gum disease is supported by dental literature and clinical guidelines. Nicotine and smokeless/combustible tobacco products induce local vasoconstriction, impair gingival fibroblast and immune cell function, alter the oral microbiome, and significantly increase the risk and progression of periodontal (gum) disease.

1:40:00Keith Humphreyssupportedhigh

Psychologist Stephen Higgins pioneered the use of contingency management reinforcement protocols for treating cocaine addiction.

"The only thing that seems to work is contingency management, which are these things where Steve Higgins, I think, was the first person to do this... He started experimenting with people addicted to cocaine, saying, 'Well, you're coming into treatment. How about tomorrow we'll do a urinalysis when you come in, and if it's a negative urinalysis, the first day we'll give you two bucks...'" (said at 1:40:00)

Stephen T. Higgins and colleagues pioneered voucher-based contingency management reinforcement protocols for the treatment of cocaine dependence in the early 1990s. In seminal studies (e.g., Higgins et al., 1991), Higgins established protocols in which patients received contingent incentives (vouchers exchangeable for retail goods/services) immediately upon submitting drug-negative urine samples, which markedly increased treatment retention and continuous cocaine abstinence compared with standard counseling approaches.

2:02:24Keith Humphreyssupportedhigh

People with substance use addiction discount future rewards significantly more steeply than non-addicted individuals, showing a strong bias toward smaller immediate rewards over larger delayed rewards.

"So all people to some extent, you know, discount future rewards to some, you know... And in addiction, they do it even more. So when in in in addiction, if you ask people about what, you know, "Would you take, you know, uh $5 today or $20 tomorrow?" they're more likely to say $5 right now, almost as if tomorrow doesn't exist." (said at 2:02:24)

Extensive meta-analytic evidence confirms that individuals with substance use disorders and addictive behaviors discount delayed monetary rewards significantly more steeply than non-addicted controls, displaying a pronounced preference for smaller immediate rewards over larger delayed rewards. Multilevel meta-analyses demonstrate moderate-to-large effect sizes comparing individuals with substance use disorders to controls across all major drug classes, and continuous meta-analyses consistently find that steeper delay discounting is robustly associated with greater addiction severity.

2:07:50Keith Humphreyssupportedmoderate

A study by Ruth Cronkite found that when men with alcoholism became sober, their wives, assessed a year later, exhibited functioning and psychological traits indistinguishable from women married to men who had never had alcoholism.

"One of the really interesting studies was done by Ruth Cronkite, who was my colleague for a while, and it was of women who were married to alcoholic men and um did, you know, all the things that fit the codependent thing, but then the when the men got sober and they went back and studied them a year later, the women looked exactly like women of men who had never been alcoholic." (said at 2:07:50)

Ruth Cronkite and Rudolf Moos (along with John Finney and colleagues at the Stanford/VA research center) conducted seminal longitudinal studies evaluating alcoholic patients, their spouses, and families following treatment compared to matched community controls. In their follow-up evaluations of post-treatment functioning, spouses and families of recovered (abstinent/sober) alcoholics showed psychological, role, and family functioning that did not significantly differ from sociodemographically matched community control families whose partners had no history of alcoholism, whereas spouses of relapsed patients continued to exhibit dysfunction and distress.

2:11:55Keith Humphreyssupportedlow

In a residential treatment study of individuals with methamphetamine addiction, cue-elicited fMRI activation in the nucleus accumbens predicted relapse, whereas participants' self-reported craving or feelings toward drug cues did not.

"So we did some work uh myself, Claudia Padula, Brian Knutson, Kelly McNairn up at the uh the VA in Menlo Park of uh people who were in a residential program addicted to methamphetamine... and uh then uh imaging them uh and showing them cues of meth-associated things like the pipe or the powder and all that and asking them, "How much do you like that? What do you feel towards that?" Well, independent of that, there's also nucleus accumbens activation that you can see, and that predicted who relapsed. Not what they said, but what there was going on in their brain." (said at 2:11:55)

The speaker accurately describes a prospective cohort study conducted with colleagues (Padula, Knutson, et al.) among patients in a residential treatment program at the VA Palo Alto Health Care System. The published study (MacNiven/Padula et al., JAMA Network Open 2018; Padula et al., 2023) showed that fMRI-measured nucleus accumbens (NAcc) response to drug cues prospectively predicted subsequent relapse (classifying relapsers and abstainers with over 75% accuracy) above and beyond conventional self-report and clinical measures.

  • supports: Association of Neural Responses to Drug Cues With Subsequent Relapse to Stimulant Use. (JAMA network open 2018) · cited 73x in the literature
    "In patients, increased drug cue response in the NAcc (but not other volumes of interest) was associated with time to relapse months later (Cox proportional hazards regression hazard ratio, 2.30; 95% CI, 1.40-3.79). After controlling for age, NAcc response to drug cues classified relapsers (12 patients; 1 woman and 11 men; mean [SD] age, 49.3 [14.1] years) and abstainers (21 patients; 1 woman and 20 men; mean [SD] age, 39.3 [12.3] years) at 3 months with 75.8% classification accuracy. Model comparison further indicated that NAcc responses to drug cues were associated with relapse above and beyond estimations of relapse according to conventional measures." (abstract, results, passage verified)
    pubmedfull study (doi)
2:18:48Keith Humphreyssupportedvery low

A patient with refractory addiction received a neurosurgical brain implant for addiction at West Virginia University.

"The only neurosurgery patient is at West Virginia University, you know, who had a very uncontrollable addiction and got not exactly sure the nature of the implant. If it's a stimulating implant, uh that's happened once. It was covered. People want to read about Lenny Bernstein, a friend of mine at Washington Post, who interviewed that that patient and the team." (said at 2:18:48)

A clinical trial at West Virginia University (led by Dr. Ali Rezai at the Rockefeller Neuroscience Institute) investigated deep brain stimulation (DBS) targeting the nucleus accumbens/ventral capsule in patients with severe, treatment-refractory opioid use disorder. The pilot trial implanted DBS devices in four participants, demonstrating feasibility and safety, and was widely reported in mainstream media including The Washington Post.

2:25:15Keith Humphreyssupportedmoderate

A study by Doug Polcin and colleagues found that 91% of individuals entering treatment for alcohol use disorder reported that someone had pressured or leaned on them in the past year to quit drinking.

"There's a study I like to quote by Doug Polcin and colleagues of people seeking help for alcohol treatment. And why this is a good one is because alcohol is legal, right? So it's not the war on alcohol made them go. Well, alcohol is legal. But he asked all of them, "Has anyone leaned on you basically to quit drinking in the past year?" And 91% of them said yes." (said at 2:25:15)

In a study by Doug Polcin and colleagues analyzing data from four National Alcohol Surveys among individuals seeking alcohol treatment (N = 476), over 90% (specifically ~91%) reported receiving pressure from at least one source (such as family, spouse, friends, physician, workplace, or legal system) to change or reduce their drinking.

2:26:33Keith Humphreyssupportedhigh

Federal mental health and addiction parity legislation passed in the United States in 2008 requiring commercial insurance plans to cover mental health and addiction benefits at comparable levels to medical and surgical benefits.

"And that was because 2008 is when parity legislation came in. This means like Blue Cross, Aetna, and all those, when they cover stuff, they have to cover mental health and addiction, too, at at at a comparable level." (said at 2:26:33)

The speaker accurately describes the 2008 Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act (MHPAEA). Passed in 2008, the federal law mandated that group health insurance plans providing mental health or substance use disorder benefits must provide them on terms no more restrictive than (at comparable levels to) coverage for general medical and surgical care.

2:22:53Keith Humphreyssupportedmoderate

Oxford House communal recovery residences, which are democratically self-run and require abstinence from drugs and alcohol, have strong scientific evidence demonstrating benefit for maintaining recovery from substance use disorders.

"there's a model called Oxford House, which is run by the people who live there, and uh they all contribute a bit to the rent, and they have a culture which is basically you can't you can't fight, you can't be violent, and you can't use substances or bring them in, but otherwise that's it. And they they have sort of recovery communities, like 10,000 of those things. Those kind of things have really good evidence of of benefit." (said at 2:22:53)

The claim is supported by scientific evidence. Oxford Houses are democratic, peer-run, self-supporting recovery residences that require total abstinence from alcohol and illicit drug use and prohibit violence. Randomized controlled clinical trials (e.g., Jason et al., 2006; 2007) demonstrate that individuals assigned to an Oxford House following substance use treatment experienced significantly lower rates of substance use relapse (15.6% vs 64.8% at 24 months for those staying 6+ months), lower incarceration rates, and higher employment rates compared to usual aftercare. A recent systematic review of recovery housing (which includes Oxford House studies) rated the level of evidence for recovery housing as moderate based on RCT and quasi-experimental data showing improved abstinence, employment, and lower cost compared to usual care.

2:33:41Keith Humphreyssupportedmoderate

The Cochrane review on Alcoholics Anonymous and 12-step facilitation found that for non-abstinence outcomes—such as reduced drinking, decreased dependence, and family functioning—AA was as effective as established psychological treatments.

"And then when you looked at other outcomes like did the person at least cut their drinking or reduce the damage of drinking or less dependent or better family, you know, functioning, whatever, it was as good as amazing for something that's free, you know." (said at 2:33:41)

The 2020 Cochrane Systematic Review by Kelly and colleagues evaluated 27 studies (10,565 participants) comparing Alcoholics Anonymous (AA) and Twelve-Step Facilitation (TSF) against established psychological interventions (such as Cognitive Behavioral Therapy and Motivational Enhancement Therapy). The review found that while AA/TSF was superior to other treatments for achieving continuous abstinence, it performed as well as established treatments on non-abstinence outcomes, including drinking intensity, alcohol-related consequences, and addiction severity.

2:38:32Keith Humphreyssupportedmoderate

Animal studies, small trials, and opportunistic epidemiological studies show a pattern of semaglutide reducing alcohol consumption.

"But when I look through animal studies, small trials, and um opportunistic epidemiological studies... I see this pattern, particularly with semaglutide, which is the GLP that is in Wegovy and Ozempic and alcohol, uh drops in alcohol use." (said at 2:38:32)

The speaker's description accurately reflects the multi-tiered body of published research on semaglutide and alcohol consumption. Animal models demonstrate that semaglutide and other GLP-1 receptor agonists reduce alcohol intake, binge drinking, and reward responses. Small randomized clinical trials (such as a 2026 double-blind RCT of weekly semaglutide in patients with alcohol use disorder and obesity) show significant reductions in heavy drinking days and craving. In addition, large opportunistic epidemiological and observational cohort studies using electronic health records consistently report reduced risks of incident and recurrent alcohol use disorder, alcohol-related hospitalizations, and overall consumption.

2:40:10Keith Humphreyssupportedhigh

GLP-1 receptor agonist drugs have been in medical use for approximately 20 years.

"the another nice thing is these are old drugs. They've been around like 20 years. People don't realize that. So, and millions and millions of people have taken them." (said at 2:40:10)

The first GLP-1 receptor agonist, exenatide (administered twice daily), was approved by the US FDA for the treatment of type 2 diabetes in 2005. GLP-1 receptor agonists have thus been in clinical use for approximately 19–20 years.

2:41:38Keith Humphreyssupportedhigh

The United States and New Zealand are the only two countries in the world that permit direct-to-consumer television advertising for prescription pharmaceuticals.

"The Lancet Commission on Stanford Lancet Commission that I led... that was one of the points we made is that there's only two countries on Earth that have television ads all the time, which is us and New Zealand." (said at 2:41:38)

The United States and New Zealand are widely documented in the biomedical and health policy literature as the only two countries globally that permit direct-to-consumer advertising (DTCA) of prescription pharmaceuticals to the general public.

2:42:15Keith Humphreyssupportedmoderate

Representative population surveys show that only a small minority of individuals who recover from substance use disorders ever received formal addiction psychiatric treatment.

"of people who had a substance problem and are now doing well in in big representative surveys, very few of them actually went to see anybody like Stanford psychiatry. That is an unusual pathway to go through addiction treatment." (said at 2:42:15)

Nationally representative population surveys (such as the National Epidemiologic Survey on Alcohol and Related Conditions, NESARC) consistently demonstrate that the majority of individuals who resolve or recover from substance use disorders do so without ever receiving formal specialty addiction treatment or psychiatric care (often termed natural or unassisted recovery). In NESARC analyses, only approximately 15% to 25% of individuals with lifetime substance use disorders or alcohol dependence reported ever utilizing formal treatment services.

4:16:26Keith Humphreyssupportedmoderate

There is very little published research data evaluating 12-step mutual-help programs for gambling addiction and sex addiction compared to substance use disorders.

"There's very little on gambling and sexual addicts, those those things. So, the the other big pool of data we have, the extent we have, is on the NA, Cocaine Anonymous, Narcotics Anonymous." (said at 4:16:26)

Published systematic reviews confirm that empirical research evaluating 12-step mutual-help fellowships for behavioral addictions—particularly Gamblers Anonymous (GA) and 12-step groups for compulsive sexual behavior—is sparse compared to the vast literature on Alcoholics Anonymous and substance use disorders (such as Narcotics Anonymous and Cocaine Anonymous). Systematic reviews note only a handful of studies evaluating GA and sexual addiction mutual-help programs, with scoping reviews highlighting the limited evidence base and a lack of large-scale randomized controlled trials.

3:03:25Keith Humphreyssupportedhigh

Genetic predisposition to addiction represents elevated risk rather than a deterministic outcome.

"Genes are risk; they're not destiny. And that's very important. Even if you come from, you know, a hundred generations worth, that doesn't mean that your life is necessarily going to going to come out that way." (said at 3:03:25)

Substance use disorders and addiction are well-established as complex, polygenic conditions influenced by both moderate-to-high heritability (typically estimated around 40–60% across twin and family studies) and environmental factors. Genetic variation confers vulnerability and altered susceptibility (risk) rather than a deterministic outcome, requiring environmental exposure and gene–environment interactions for the disorder to develop.

3:10:25Keith Humphreyssupportedhigh

Exposure reduces phobic fear and anxiety, whereas avoidance exacerbates fear.

"and I know about phobia, like the most basic thing is exposure, you know, reduces fear and anxiety. Running away from things makes them scarier." (said at 3:10:25)

The speaker accurately states the foundational principles of exposure therapy and behavioral models of phobia. Extensive meta-analyses of randomized controlled trials demonstrate that exposure therapy (in vivo or virtual reality, single-session or multi-session) produces large reductions in phobia symptoms, fear, and avoidance behavior. Furthermore, research on avoidance and safety behaviors confirms that avoiding feared stimuli prevents fear extinction and corrective learning, thereby maintaining and exacerbating phobic fear and anxiety over time.

3:18:58Keith Humphreyssupportedmoderate

The gender ratio for alcohol use disorder is approximately 60% male to 40% female.

"alcohol probably about 60/40. You know, used to be higher, but women have been drinking more." (said at 3:18:58)

Large-scale epidemiological studies and national surveys (such as NESARC and NSDUH) confirm that the historical male-to-female gap in alcohol use disorder (AUD) has significantly narrowed over recent decades due to increasing alcohol consumption and AUD prevalence among women. Current estimates for AUD in the United States and other developed nations place the sex ratio at approximately 1.5:1 (roughly 60% male to 40% female), with even narrower differences observed among adolescents and young adult cohorts.

3:19:06Keith Humphreyssupportedmoderate

Prescription medication addiction has a roughly equal gender ratio of 50/50 between men and women in clinical settings.

"The one thing you see in clinics that is close—the one is prescription medication. That those are those are a little closer to 50/50, but otherwise it's predominantly male." (said at 3:19:06)

Epidemiological and clinical evidence supports the claim. While substance use disorders (SUDs) and illicit drug use (such as heroin) have historically been and remain predominantly male (with heroin use approximately twice as common in men), prescription medication misuse and dependence (such as prescription opioids and sedatives) exhibit a much narrower gender gap, approaching a 50/50 sex ratio. Large-scale population surveys (such as the National Survey on Drug Use and Health) and clinical trials demonstrate that women initiate prescription opioid misuse at rates equal to or higher than men and represent a substantially higher proportion of prescription drug misuse compared to illicit drug use disorders.

3:21:13Keith Humphreyssupportedmoderate

Addiction relapse is most likely to occur during periods of stress, such as interpersonal conflict or sleep deprivation.

"Broadly speaking, though, relapse is most likely in times of, you know, stress, you know, whether that's, uh, transitory stress like, uh, you know, spat with the spouse or with the boss, or I'm just really, you know, I was exhausted. Um, you know, didn't didn't sleep well a couple nights in a row, that kind of thing." (said at 3:21:13)

Extensive preclinical, neuroimaging, and clinical literature confirms that acute and transitory stressors—such as social/interpersonal conflict and acute sleep disturbance or deprivation—are major triggers of craving and significantly increase the risk of relapse across substance use disorders.

7 No source found (not proven false)
0:21:17Keith Humphreysunverifiedlow

For most health outcomes, the physical damage per alcoholic drink is greater for women than for men, partly due to differences in body size and hormonal factors.

"And the damage per drink is more for women for most things than it is for men, partly due to body size, but also partly probably due to some hormonal things." (said at 0:21:17)

No matching publications were retrieved within the search budget to directly verify the specific claim. While broad epidemiological and toxicological literature recognizes that biological females generally experience higher blood alcohol concentrations per standard drink (owing to smaller body size, lower total body water volume, and differing gastric alcohol dehydrogenase levels) and higher relative risk for certain conditions (such as alcoholic liver disease and cardiomyopathy) per unit of alcohol consumed, this specific claim could not be formally verified against fetched database records.

1:01:03Andrew Huberman (host)unverifiedvery low

Slot machines previously accounted for a small fraction of casino revenue, but now account for 80% or more.

"And it turns out that slot machines used to be a small fraction of what the of the income of casinos. Now it's 80% or more." (said at 1:01:03)

No scholarly publications or industry records could be fetched to verify the exact historical and contemporary proportions of casino revenue generated by slot machines. While industry literature often notes that slot machines historically represented a minor share compared to table games and now generate the majority (often 60% to 80% or more depending on the jurisdiction), this specific claim could not be directly verified against fetched scholarly records.

1:29:08Andrew Huberman (host)unverifiedvery low

More than 70% of prescription antidepressant medications globally are consumed in the United States.

"Not pushing back for sake of pushing back, but I've seen data—I don't know how solid the data are—that something like 70-plus percent of the prescription drugs for depression are consumed by the United States." (said at 1:29:08)

No published epidemiological studies or health statistics databases indexed in PubMed or Europe PMC were located that support the claim that the United States accounts for over 70% of global prescription antidepressant consumption. Comparative international data on antidepressant utilization (such as OECD health statistics) show high per-capita consumption across multiple high-income countries (including Iceland, Canada, Australia, Portugal, and the United Kingdom), making a >70% global volume share for the US biologically and demographically unverified in the peer-reviewed literature.

2:36:48Keith Humphreysunverifiedvery low

Twelve-step facilitation counseling produces much lower rates of uptake and attendance for illicit drug mutual-help groups like Cocaine Anonymous and Narcotics Anonymous than it does for Alcoholics Anonymous.

"there was uh what's called 12-step facilitation counseling... And the uptake was much lower. So, if you do that in a in an alcohol program, you know, you get these, you know, doubling or tripling of the rate of patients going into AA. And the effect was much, much smaller to to with with the illicit drugs to get people to attend CA." (said at 2:36:48)

No published comparative trial or meta-analysis was retrieved directly contrasting the relative effect sizes or uptake rates of Twelve-Step Facilitation (TSF) counseling for illicit drug mutual-help groups (such as Cocaine Anonymous or Narcotics Anonymous) versus Alcoholics Anonymous. While TSF interventions have been studied across both alcohol use disorder (e.g., Project MATCH) and illicit stimulant use disorders (e.g., the STAGE-12 trial), the specific assertion that uptake/attendance effects are dramatically smaller for illicit drug mutual-help groups remains unverified.

2:39:15Keith Humphreysunverifiedlow

Individuals with an alcohol use disorder are approximately 70% more likely to also be overweight.

"if you have a drinking problem, you're about 70% more likely to also be overweight, and Americans already pretty overweight." (said at 2:39:15)

A specific epidemiologic finding that individuals with an alcohol use disorder or 'drinking problem' are approximately 70% more likely (or have an odds ratio of ~1.7) to be overweight could not be confirmed in the fetched literature. While co-occurring alcohol use disorder and obesity/overweight have been examined in nationally representative cohorts (such as in JAMA Internal Medicine), the exact relative risk or odds ratio cited by the speaker was not verified.

4:14:42Keith Humphreysunverifiedlow

Alcoholics Anonymous operates meetings and has a presence in approximately 195 countries.

"Like 195 countries or something have AA in it." (said at 4:14:42)

No scholarly publications could be retrieved to verify the specific claim that Alcoholics Anonymous has a presence in approximately 195 countries. General literature commonly estimates that AA operates in roughly 180 countries with over 2 million members, but without fetched records to verify this comparison directly, the claim remains unverified.

3:07:41Keith Humphreysunverifiedvery low

The original edition of Alcoholics Anonymous was nicknamed the 'Big Book' because it was printed on cheap, thick paper during the Great Depression to make it look substantial.

"It's actually just was called the Big Book because it was printed on cheap paper, so it was sort of fat and pulpy. This was back in the Depression, right?" (said at 3:07:41)

No scholarly publication directly evaluating or documenting the specific printing history and origins of the nickname 'Big Book' regarding the choice of cheap, thick paper during the Great Depression was located within the fetched scholarly literature. While historical lore from Alcoholics Anonymous suggests the original 1939 first edition was intentionally printed on thick paper to make the volume appear more substantial and justify its price, this specific claim was not verified in the retrieved records.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.